

1 Title: Comparison Of New and emerging SARS-CoV-2 variant Transmissibility through  
2 Active Contact Testing. A comparative cross-sectional household seroprevalence study.

3

4 Short Title: Comparing new and emerging SARS-CoV-2 variant transmissibility

5

6 Author list:

7 \*KM Gaskell<sup>1</sup>, \*N El Kheir<sup>1</sup>, M Mirfendesky<sup>2</sup>, T Rampling<sup>3</sup>, M Marks<sup>4</sup>, C F Houlihan<sup>5</sup>, N  
8 Lemonge<sup>6</sup>, H Bristowe<sup>6</sup>, S Aslam<sup>6</sup>, D Kyprianou<sup>2</sup>, E Nastouli<sup>7</sup>, D Goldblatt<sup>8</sup>, K Fielding<sup>9</sup>,  
9 DAJ Moore<sup>1</sup> & CONTACT team (field team)

10

11 \*These authors contributed equally to this work.

12 Corresponding author: KM Gaskell [kate.gaskell@lshtm.ac.uk](mailto:kate.gaskell@lshtm.ac.uk)

13

14 Affiliations:

15 1 Clinical Research Department, Faculty of Infectious and Tropical Diseases,  
16 London School of Hygiene and Tropical Medicine, London, United Kingdom

17 2 North Middlesex University Hospital NHS Trust, London, United Kingdom

18 3 Hospital for Tropical Diseases, University College Hospital London; University College  
19 Hospital London; Division of Infection and Immunity, University College London, London,  
20 United Kingdom

21 4 Clinical Research Department, London School of Hygiene and Tropical Medicine; The  
22 Hospital for Tropical Diseases; Division of Infection and Immunity, University College  
23 London, London, United Kingdom

24 5 Department of Clinical Virology, University College Hospital London; Division of  
25 Infection and Immunity, University College London, London, United Kingdom

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

26 6 London School of Hygiene and Tropical Medicine, London, United Kingdom  
27 7 Department of Clinical Virology, University College London Hospitals NHS Foundation  
28 Trust; Department of Population, Policy and Practice, University College London Institute of  
29 Child Health, London, United Kingdom  
30 8 Infection, Immunity & Inflammation Department University College London; Great  
31 Ormand Street Institute of Child Health, London, United Kingdom  
32 9 Infectious Disease Epidemiology Group, London School of Hygiene and Tropical  
33 Medicine, London, United Kingdom  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 *The Corresponding Author has the right to grant on behalf of all authors and does grant on*  
52 *behalf of all authors, an exclusive licence (or non exclusive for government employees) on a*  
53 *worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be*  
54 *published in BMJ editions and any other BMJ PGL products and sublicences such use and*  
55 *exploit all subsidiary rights, as set out in our licence.*  
56

57 *"All authors have completed the Unified Competing Interest form (available on request from*  
58 *the corresponding author) and declare: no support from any organisation for the submitted*  
59 *work [or describe if any]; no financial relationships with any organisations that might have*  
60 *an interest in the submitted work in the previous three years [or describe if any], no other*  
61 *relationships or activities that could appear to have influenced the submitted work [or*  
62 *describe if any]."*  
63

64 Copyright

65 *"I, the Submitting Author has the right to grant and does grant on behalf of all authors of the*  
66 *Work (as defined in the author licence), an exclusive licence and/or a non-exclusive licence*  
67 *for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed*  
68 *a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US*  
69 *Federal Government officers or employees acting as part of their official duties; on a*  
70 *worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ")*  
71 *its licensees.*

72 *The Submitting Author accepts and understands that any supply made under these terms is*  
73 *made by BMJ to the Submitting Author unless you are acting as an employee on behalf of*  
74 *your employer or a postgraduate student of an affiliated institution which is paying any*  
75 *applicable article publishing charge ("APC") for Open Access articles. Where the*  
76 *Submitting Author wishes to make the Work available on an Open Access basis (and intends*  
77 *to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a*  
78 *Creative Commons licence – details of these licences and which licence will apply to this*  
79 *Work are set out in our licence referred to above."*

80 *I affirm that the manuscript is an honest, accurate, and transparent account of the study*  
81 *being reported; that no important aspects of the study have been omitted; and that any*  
82 *discrepancies from the study as planned (and, if relevant, registered) have been explained.*  
83

84 *This research was funded by the LSHTM COVID-19 response fund Grant number*  
85 *DONAT15914 and performed independently to any intervention by this funder.*  
86

87

88

89

90

## 91 Abstract

92 Historically SARS-CoV-2 secondary attack rates (SAR) have been based on PCR  
93 positivity on screening symptomatic contacts, this misses transmission events and identifies  
94 only symptomatic contacts who are PCR positive at the time of sampling. We used serology to  
95 detect the relative transmissibility of Alpha Variant of Concern (VOC) to non-VOC SARS-  
96 CoV-2 to calculate household secondary attack rates. We identified index patients diagnosed  
97 with Alpha and non-VOC SARS-CoV-2 across two London Hospitals between November  
98 2020 and January 2021 during a prolonged and well adhered national lockdown. We completed  
99 a household seroprevalence survey and found that 61.8% of non-VOC exposed household  
100 contacts were seropositive compared to 82.1% of Alpha exposed household contacts. The odds  
101 of infection doubled with exposure to an index diagnosed with Alpha. There was evidence of  
102 transmission events in almost all households. Our data strongly support that estimates of SAR  
103 should include serological data to improve accuracy and understanding.

104

## 105 Key Messages

106 Secondary attack rates (SAR) in SARS-CoV-2 were previously calculated using PCR positive  
107 samples only, it is more accurate to use a household transmission model and screen contacts  
108 using serology, as done in this study. SAR should include serological data to improve accuracy  
109 and understanding. All households in this study had transmission events. SAR were 61.8% in  
110 non-VOC SARS-CoV-2 exposed household contacts compared to 82.1% in Alpha SARS-  
111 CoV-2 exposed household contacts.

112

113

114

115

116

117

## 118 [Introduction](#)

119           In autumn 2020 the first SARS-CoV-2 variant of concern (VOC) B.1.1.7 was reported  
120 in Southeast England. National incidence was tracked by Public Health England through the  
121 failure of routine SARS-CoV-2 PCRs to detect the spike gene (spike gene target failure, SGTF)  
122 in community samples. Initial modelled estimates of the infectiousness of B.1.1.7.  
123 (subsequently named Alpha) ranged between 43-100% more transmissible than the previously  
124 circulating wild type SARS-CoV-2 virus(1,2).

125           One empiric metric of transmissibility for infectious diseases is the secondary attack  
126 rate (SAR) in exposed contacts. To date, reporting of SAR in SARS-CoV-2 has mostly defined  
127 secondary infection as contemporary PCR positivity in a symptomatic contact(3). This  
128 approach significantly underestimates the total number of people infected by only capturing  
129 those who are both symptomatic and still have detectable viral RNA at the time of sampling.

130           Historically, reported SARS-CoV-2 secondary attack rates based upon PCR-positivity  
131 were approximately 20% overall, irrespective of variant (4), though this was reported to rise to  
132 around 40% for Omicron (4,5).

133           Serological testing captures previous infection, whether symptomatic or not, including  
134 potentially missed transmission events from which the contact has become PCR-negative by  
135 the time of sampling. Comparison of SARs between settings or viral variants should thus  
136 incorporate serological responses if the true transmissibility is to be understood. In a study  
137 from Singapore, PCR testing of symptomatic household contacts (HHC) found a SAR of 5.9%  
138 (95%CI 4.9-7.1), but bayesian modelling of serological data estimated 62% of infections were  
139 missed (6).

140 In March 2021, four months into a national ‘lockdown’, we set out to compare the  
141 measured transmissibility of the Alpha variant of SARS-CoV-2 relative to other  
142 contemporaneously circulating variants (referred to as non-VOC) using serology and aimed to  
143 determine household SAR from index patients diagnosed with SARS-CoV-2 across two  
144 London Hospitals between November 2020 and January 2021.

## 145 [Methods](#)

146 We performed a cross sectional seroprevalence study of HHC of individuals who had  
147 SARS-CoV-2 detected and whose virus was successfully whole genome sequenced (WGS)  
148 between 9th November 2020 and 31st January 2021. This time period was selected as both  
149 Alpha and non-VOC SARS-CoV-2 were concurrently circulating within the community.  
150 Symptomatic index patients who were diagnosed across two North London hospitals (Hospital  
151 #1 and Hospital #2) were invited to participate alongside all of their HHC. Potential  
152 participants were identified from those who submitted any sample where SARS-CoV-2 was  
153 detected by PCR to either laboratory including those submitted from the Emergency  
154 Department, out of hours GP services, occupational health services and hospitalised patients.  
155 We collected telephone verbal consent and undertook a questionnaire, subsequently visiting  
156 households once to collect serum for serological testing from all consenting household  
157 members. All household members of any age were eligible to participate. We initiated  
158 recruitment on 26<sup>th</sup> March 2021 for hospital #1 index cases and on 11<sup>th</sup> May 2021 for hospital  
159 #2. Recruitment was completed by 11<sup>th</sup> July 2021. The questionnaire included data on the index  
160 case, age, gender, ethnicity, and severity of COVID-19 disease, and for each contact on the  
161 duration of household exposure to the index patient whilst they were symptomatic, intensity of  
162 contact, additional SARS-CoV-2 exposures, vaccination status, and history of COVID-19  
163 diagnosis or SARS-CoV-2 detection.

## 164 [Patient and Public Involvement](#)

165 Patient and public engagement was sought at the local ethical approvals stage. The in-  
166 hospital patient advice and liaison service, the palliative care service and patient representatives  
167 were involved in how best to approach patients, relatives, and relatives of the deceased. The  
168 research question, study design and outcome measures were not altered by this engagement,  
169 but operational research procedures were adapted to incorporate patient and relative priorities  
170 and preferences. Patients were not involved in the recruitment or conduct of the study.  
171 Participant serology results were sent to all who had a serum sample taken and the final results  
172 will be emailed to all participants on publication.

### 173 [Laboratory analysis](#)

174 Samples were analysed for presence of IgG to SARS-CoV-2 spike protein (S) and  
175 nucleocapsid protein (NC) for both non-VOC and Alpha SARS-CoV-2 using a multiplex  
176 chemiluminescence immunoassay (MSD, Rockville, MD) evaluated by our laboratory as  
177 previously described(7). All households were provided with their results.

### 178 [Statistical analysis](#)

179 Assuming a conservative 15% seroprevalence in non-VOC households (8,9) and an  
180 average cluster size of 2 (for a household size of 3; it is 2.4 in southeast England) we estimated  
181 that 292 Alpha and 292 non-VOC households (1168 participants) would provide 90% power  
182 to detect a 50% increase in seropositivity. For the primary outcome of interest, we used IgG  
183 reactivity to SARS-CoV-2 NC rather than IgG reactivity to S to confirm previous SARS-CoV-  
184 2 infection to avoid any effect of vaccination status. We subsequently undertook a secondary  
185 analysis with additional inclusion of unvaccinated IgG SARS-CoV-2 S reactive and IgG NC  
186 unreactive individuals to the primary outcome and assigned them as infected contacts. We  
187 fitted a multivariable random effects logistic regression model adjusted for clustering at the  
188 household level. We considered IMD rank, interval between index PCR diagnosis and HHC

189 serum sampling and duration, and intensity of exposure to an infectious household index case  
190 as potential confounders and adjusted for these in our multivariable model.

## 191 Definitions

192 HHC were defined as individuals living in the same household as the index case at the  
193 time of PCR-confirmed SARS-CoV-2. Duration of exposure was defined as the number of  
194 days of unquarantined exposure that a HHC had with the index case from the onset of  
195 symptoms up to hospital admission or symptom resolution. Symptom duration captured the  
196 number of days the index was symptomatic at home. Socioeconomic status was captured  
197 through the use of the Index of Multiple Deprivation (IMD) which assigns nationwide ranking  
198 by postcode in the UK. Data were analysed by decile and rank. Long COVID was captured if  
199 participants had a clinical diagnosis of Long COVID.

## 200 Ethics

201 The study was approved by the London School of Hygiene & Tropical Medicine Ethics  
202 Committee (LEO ref:25265), the NHS Health Research authority (IRAS ref:295376), and local  
203 hospital review committees. Verbal informed consent was obtained during the telephone  
204 survey and written consent provided prior to phlebotomy. Parents provided written consent for  
205 children under 10 and assent was collected for children over 10 years. The study was sponsored  
206 by LSHTM.

## 207 Results

208 During the study period a total of 1366 individuals tested positive for SARS-CoV-2  
209 across the two sites and had viral genotyping data available. Of these 354 index participants  
210 agreed to take part and ultimately 238 index participants (50 non-VOC and 188 Alpha) and  
211 454 household contacts completed the study questionnaires and had a serum sample available.  
212 (figure 1).

213 We collected blood samples from 102 HHC exposed to an index with non-VOC SARS-  
214 CoV-2 infection and 352 HHC exposed to an index with Alpha SARS-CoV-2 infection. The  
215 characteristics of the 386 participants who declined a serum sample but provided survey  
216 information did not differ significantly from those providing serum (supplementary table 1).

217 The characteristics of index cases are shown by index case Alpha/non-VOC  
218 assignment, in table 1. 95% of index cases reported having been symptomatic, 76% reported  
219 respiratory symptoms and 67% were hospitalised, for a median of 9 days (IQR 4-21). There  
220 were no statistically significant differences between index cases with non-VOC and Alpha  
221 SARS-CoV-2 infection (Table 1).

222 Overall, the HHC study population was 56% female with a median age of 42 years  
223 (IQR 23–59). Median household size was three (IQR 2-4, range 2-9) with 46% of index cases  
224 reporting their ethnicity as white, 18% as black African or black Caribbean and 13% as south  
225 Asian. Compared to contacts from non-VOC index households, HHC of Alpha index cases  
226 reported a greater average duration of exposure to their infectious index case, and to report a  
227 diagnosis of symptomatic COVID-19 around the time of their index case’s diagnosis (Table  
228 2).

### 229 [Spectrum of clinical features in seropositive contacts in Alpha and non-VOC affected](#) 230 [households](#)

231 A diagnosis of SARS-CoV-2 contemporaneous to the index case diagnosis was  
232 reported by 47% and 67% of contacts exposed to non-VOC and Alpha index cases within the  
233 household respectively (48/102 vs. 235/352, chi squared p value = 0.02). Not all contacts who  
234 reported a diagnosis of COVID were symptomatic at the time, however either COVID  
235 symptoms or a SARS-CoV-2 diagnosis around the time of index case diagnosis were more  
236 frequently reported by contacts of an Alpha index case (OR 4.87, 95%CI 3.67-21.18; p<0.001);  
237 anti-nucleocapsid IgG titres were higher in those reporting symptoms (figure 2).

## 238 Seroprevalence in household contacts

239 61.8% (63/102) of non-VOC SARS-CoV-2 exposed HHC were seropositive compared  
240 to 82.1% (289/352) of Alpha SARS-CoV-2 exposed HHC. Household contacts exposed to an  
241 index with the Alpha variant had a 3.5-fold increased odds of being nucleocapsid seropositive  
242 (OR 3.5, 95%CI 1.7-7.4; p=0.001) when adjusted for household clustering.

243 The percentage of households in which no contacts had demonstrable SARS-CoV-2  
244 anti-nucleocapsid antibodies, implying a complete absence of household transmission, was  
245 3/50 (6%) and 1/188 (0.5%) in non-VOC and Alpha affected households respectively (Fisher's  
246 exact p value = 0.008).

247 Several covariates were identified as confounders requiring adjustment in logistic regression  
248 analyses, including IMD rank, interval between index PCR diagnosis and HHC serum sampling  
249 and duration and intensity of exposure to an infectious household index case (table 3).

250 Non-VOC strains of SARS-CoV-2 presented in index cases earlier within the study  
251 period and earlier within the pandemic wave. Index cases with Alpha SARS-CoV-2 presented  
252 later within the pandemic wave and became the dominant strain causing COVID-19. The  
253 interval between index PCR diagnosis and HHC serological testing differed between the Alpha  
254 and non-VOC groups, (Supplementary figure 1, table 4). The observed decay in anti-  
255 nucleocapsid IgG titres over time (supplementary figure 2) highlights the importance of  
256 accounting for this differential delay; longer delay increases the risk of decay of anti-NC IgG  
257 below the threshold of detection and consequent misclassification of infected HHCs as  
258 seronegative, uninfected subjects.

259 Table 4 highlights the difference in median follow up time according to detection of  
260 IgG to S and NC, stratified by vaccination status (vaccination generates anti-S but not anti-NC  
261 IgG antibodies). The falling IgG NC titre over time did impact the odds of seropositivity in  
262 HHCs. This contrasts with previous published work where nucleocapsid titre declines more

263 rapidly over the first 6 months from infection than Spike protein titre but does not impact  
264 positivity overall.

265 To improve the classification of infection and explore the effect of Alpha exposure  
266 further we performed a secondary analysis using a combined outcome definition of infection  
267 including all NC IgG positive contacts and unvaccinated participants seropositive for anti-S  
268 IgG (supplementary figure 3) we found a similar effect to in our main analysis. We performed  
269 an unadjusted and an adjusted logistic regression model with this outcome, adjusting for the  
270 same confounding exposures, which yielded similar though slightly lower point estimates  
271 (aOR 2.1, 95%CI 0.8-5.5) (table 5).

## 272 Discussion

273 The most striking finding of our study is the very high secondary infection rate amongst  
274 household contacts of SARS-CoV-2 irrespective of variant; 62% in non-VOC exposed and  
275 82% in Alpha exposed contacts. The odds of infection in a household contact, already high  
276 with the original SARS-CoV-2 virus, doubled with the arrival of Alpha. Very few households  
277 were identified in which no transmission had taken place (6% and 0.5% of non-VOC and Alpha  
278 households respectively). A recently published human challenge model of pre-Alpha SARS-  
279 CoV-2 identified viral shedding onset within 2 days of infectious exposure continuing up to 12  
280 days post-inoculation (10). Our data demonstrate a dose-response of exposure to transmission,  
281 supporting the suggestion that being able to isolate from household members mitigates against  
282 transmission of SARS-COV-2 to some extent, regardless of the strain or variant.

283 These data, capturing evidence of infection previously overlooked by highly time-  
284 sensitive estimates of SAR dependent upon PCR testing of contacts, demonstrate much higher  
285 rates of infection than have been previously reported (11). In addition to the effect of Alpha,  
286 household contacts were much more likely to be infected with greater duration and higher  
287 intensity of exposure in a dose-response fashion. Whilst Omicron, is believed to have

288 outcompeted and causes more infections than previous VOCs , due in part to a high rate of re-  
289 infections in the partially immune (11) Danish data reported a household secondary attack rate  
290 using RT-PCR of only 31% and 21% in Omicron and Delta SARS-CoV-2 infections  
291 respectively(12). A meta-analysis of household SARs for Alpha and Delta VOC were  
292 estimated at 38% and 30.8% respectively (4). These reports are significantly lower than our  
293 study findings. Most previous data included secondary cases identified RT-PCR positive  
294 infections only (12). A previous study assessing a composite secondary attack rate using both  
295 serology and PCR results in Los Angeles found a similarly high SAR of 77% to our study (13).  
296 Our data strongly support that estimates of SAR should include serological data to improve  
297 accuracy and understanding.

298 Our original analysis focussed upon anti-nucleocapsid IgG as the marker of infection  
299 as earlier data had suggested this should remain detectable within the timeframe that our study  
300 was planned for. In the event, recruitment was delayed longer than expected and some anti-NC  
301 IgG decay was seen earlier than previously reported(11). To capture those who we believed to  
302 have been infected but in whom anti-NC IgG was undetectable (or no longer detectable at the  
303 threshold of the test) we took advantage of the unvaccinated contacts with only anti-S IgG to  
304 improve our definition of infection. The lower adjusted odds ratio of 2.1 is thus more likely to  
305 be closer to the true value.

306 Our study has several limitations. Firstly, an assumption of all our analyses is that the  
307 most likely explanation for a household contacts seropositivity is their household exposure. It  
308 is plausible that exposure may have occurred during the first wave of infections in England  
309 which started in March 2020, or indeed outside the household at any time including to a  
310 common source at the same time as the index. Any such effect would tend to exaggerate the  
311 odds in Alpha contacts, because Alpha infections came later, allowing for greater exposure-  
312 risk time. However, low population prevalence prior to November 2020 and societal lockdown

313 conditions in England will have minimised this effect, although adherence to lockdown was  
314 dwindling during the emergence of Alpha. We have no local data for community prevalence  
315 during the period studied.

316 Secondly, the index cases in this study were tested and diagnosed in hospital  
317 laboratories so may have been more severely unwell than the general population. Whilst this  
318 might bias overall estimates of the SAR, we did not find any evidence of difference in severity  
319 between the two exposure groups and so this is unlikely to have impacted our finding of an  
320 increased SAR amongst contacts of Alpha infection. The increased severity may have resulted  
321 in higher rates of viral shedding and more prolonged viral shedding, however those with more  
322 severe illness in this population were admitted to hospital, interrupting domiciliary  
323 transmission. We cannot present data on the viral loads or cycle thresholds (CT) for PCR  
324 positive index patients as a variety of PCR platforms were used across the laboratories  
325 involved, some of which reported relative light units. There are reported differences between  
326 variants in viral loads, duration of shedding, and in duration of infectivity (15–17)our data  
327 cannot be directly extrapolated to more recent VOCs.

328 Finally, we were unable to meet our planned sample size within the available time  
329 frame to complete the study prior to relaxation of lockdown regulations, in part due to delays  
330 in regulatory and ethics application approvals. Community uptake and participation with the  
331 study was lower than anticipated both at initial approach and for the follow up serum sample.  
332 Despite this we were still able to demonstrate the increased SAR for Alpha compared to non-  
333 VOC infections and that using serology resulted in a markedly higher estimate of the SAR for  
334 both VOC and non-VOC infections.

335 Secondary attack rates amongst household contacts are a direct measure of  
336 transmissibility, particularly if community transmission is not high. There is however a risk  
337 that saturation - almost all contacts becoming infected - can obscure differences between

338 infecting strains. Careful participant selection minimises the risk of confounding by time, place  
339 or person allowing the rates of secondary infection and secondary disease to be directly  
340 estimated and compared between different virus variants. Calculating transmissibility for novel  
341 and previous VOC(s) is an essential component of the public health response. These data  
342 support our argument to include serology in calculating secondary attack rates to more  
343 accurately assess transmissibility of new SARS-CoV-2 VOCs. Household screening to assess  
344 SAR is a useful model to replicate in future variant driven pandemic waves.

345  
346

## 347 [References](#)

- 348  
3491. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated  
350 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science*. 2021 Apr  
351 9;372(6538):eabg3055.
3522. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing transmissibility of  
353 SARS-CoV-2 lineage B.1.1.7 in England. *Nature*. 2021 May;593(7858):266–9.
3543. Miller E, Waight PA, Andrews NJ, McOwat K, Brown KE, Höschler K, et al. Transmission of SARS-  
355 CoV-2 in the household setting: A prospective cohort study in children and adults in England. *J*  
356 *Infect*. 2021 Oct 1;83(4):483–9.
3574. Madewell ZJ, Yang Y, Longini IM, Halloran ME, Dean NE. Household secondary attack rates of  
358 SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis.  
359 *MedRxiv Prepr Serv Health Sci*. 2022 Jan 11;2022.01.09.22268984.
3605. Águila-Mejía JD, Wallmann R, Calvo-Montes J, Rodríguez-Lozano J, Valle-Madrazo T, Aginagalde-  
361 Llorente A. Secondary Attack Rate, Transmission and Incubation Periods, and Serial Interval of  
362 SARS-CoV-2 Omicron Variant, Spain - Volume 28, Number 6—June 2022 - *Emerging Infectious*  
363 *Diseases journal* - CDC. [cited 2022 May 24]; Available from:  
364 [https://wwwnc.cdc.gov/eid/article/28/6/22-0158\\_article](https://wwwnc.cdc.gov/eid/article/28/6/22-0158_article)

3656. Ng OT, Marimuthu K, Koh V, Pang J, Linn KZ, Sun J, et al. SARS-CoV-2 seroprevalence and  
366 transmission risk factors among high-risk close contacts: a retrospective cohort study. *Lancet Infect*  
367 *Dis.* 2021 Mar 1;21(3):333–43.
3687. Johnson M, Wagstaffe HR, Gilmour KC, Mai AL, Lewis J, Hunt A, et al. Evaluation of a novel  
369 multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2. *J Clin Virol.*  
370 2020 Sep 1;130:104572.
3718. Amirthalingam G, Whitaker H, Brooks T, Brown K, Hoschler K, Linley E, et al. Seroprevalence of  
372 SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social  
373 Measures, London, UK. *Emerg Infect Dis.* 2021 Jul;27(7):1795–801.
3749. Madewell ZJ, Yang Y, Longini IM, Halloran ME, Dean NE. Household Transmission of SARS-CoV-  
375 2: A Systematic Review and Meta-analysis. *JAMA Netw Open.* 2020 Dec 14;3(12):e2031756.
37610. Killingley B, Mann AJ, Kalinova M, Boyers A, Goonawardane N, Zhou J, et al. Safety, tolerability  
377 and viral kinetics during SARS-CoV-2 human challenge in young adults. *Nat Med.* 2022  
378 May;28(5):1031–41.
37911. Grandjean L, Saso A, Ortiz AT, Lam T, Hatcher J, Thistlethwayte R, et al. Long-Term Persistence of  
380 Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-  
381 CoV-2. *Clin Infect Dis [Internet].* 2021 Jul 4 [cited 2021 Jul 20];(ciab607). Available from:  
382 <https://doi.org/10.1093/cid/ciab607>
38312. Willett BJ, Grove J, MacLean OA, Wilkie C, Logan N, Lorenzo GD, et al. The hyper-transmissible  
384 SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in  
385 cell entry mechanism [Internet]. 2022 Jan [cited 2022 Jan 20] p. 2022.01.03.21268111. Available  
386 from: <https://www.medrxiv.org/content/10.1101/2022.01.03.21268111v1>
38713. Lyngse FP, Kirkeby C, Halasa T, Andreasen V, Skov RL, Møller FT, et al. Nationwide study on  
388 SARS-CoV-2 transmission within households from lockdown to reopening, Denmark, 27 February  
389 2020 to 1 August 2020. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2022  
390 Feb;27(6).

39114. Tanaka ML, Marentes Ruiz CJ, Malhotra S, Turner L, Peralta A, Lee Y, et al. SARS-CoV-2  
392 Transmission Dynamics in Households With Children, Los Angeles, California. *Front Pediatr.*  
393 2021;9:752993.
39415. Frampton D, Rampling T, Cross A, Bailey H, Heaney J, Byott M, et al. Genomic characteristics and  
395 clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome  
396 sequencing and hospital-based cohort study. *Lancet Infect Dis* [Internet]. 2021 Apr 12 [cited 2021 Jun  
397 24];0(0). Available from: [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(21\)00170-](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00170-5/abstract)  
398 [5/abstract](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00170-5/abstract)
39916. Kidd M, Richter A, Best A, Cumley N, Mirza J, Percival B, et al. S-variant SARS-CoV-2 lineage  
400 B1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath  
401 RT-qPCR. *J Infect Dis.* 2021 Feb 13;jjab082.
40217. Lee JY, Wing PA, Gala DS, Noerenberg M, Järvelin AI, Titlow J, et al. Absolute quantitation of  
403 individual SARS-CoV-2 RNA molecules provides a new paradigm for infection dynamics and variant  
404 differences. Davenport MP, editor. *eLife.* 2022 Jan 20;11:e74153.

405

#### 406 [Acknowledgement](#)

407 The authors acknowledge all the participants and their patients involved in this research and  
408 the entire CONTACT field team for their hard work throughout this project.

#### 409 [Data sharing statement](#)

410 The authors will share all de-identified participant data on request

411

412

413

414

415

416

417 Table 1

418 Baseline characteristics of 238 index cases stratified by index case Alpha or non-VOC SARS-

419 CoV-2 status

		Non-VOC index case household	Alpha index case household
Number of index - n		50	188
<b>Index characteristics</b>			
index case female - n (%)		26 (52)	111 (59)
Index case age – median (IQR)		56 (45-72)	57 (47-69)
ethnicity	white (%)	27 (54)	96 (51)
	Asian (%)	2 (4)	14 (8)
	Black (%)	7 (14)	34 (18)
	Middle Eastern (%)	5 (10)	10 (5)
	SE Asian (%)	7 (14)	13 (7)
	other	2 (4)	20 (10)
Hospital site	Hospital 1	20 (40)	88 (47)
	Hospital 2	30 (60)	100 (54)

index case respiratory symptoms <sup>1</sup> – n (%)	35 (70)	146 (78)
symptom duration in days – median(IQR)	7 (3-10)	7 (5-14)
index case hospitalisation – n (%)	29 (58)	124 (66)
index case ICU admission – n (%)	5 (17)	35 (29)
index case mortality – n(%)	1 (2)	2 (1)

420 <sup>1</sup> any of cough, dyspnoea, flu-like symptoms

421 [Table 2](#)

422 [Baseline characteristics of 454 household contacts stratified by index case Alpha or non-VOC](#)

423 [SARS-CoV-2 status](#)

		Non-VOC index case household	Alpha index case household
Number of contacts - n		102	352
<b>Index Characteristics</b>			
HHC exposed to a female index - n (%)		58 (57)	197 (56)
Index age HHC exposed to - median (IQR)		62 (45-76)	56 (47-69)
HHC exposed to index ethnicity	white (%)	47 (46)	163 (46)
	Asian (%)	6 (6)	24 (7)
	Black (%)	11 (11)	72 (21)

	Middle Eastern (%)	14 (14)	19 (5)
	SE Asian (%)	21 (21)	39 (11)
	other	3 (3)	35 (10)
Hospital site	Hospital 1	49 (48)	173 (49)
	Hospital 2	53 (52)	179 (51)
household size – median (IQR)		3 (2-4)	3 (2-4)
HHC exposed to index case respiratory symptoms <sup>1</sup> – n (%)		71 (70)	276 (78)
HHC exposure to symptomatic index in days – median (IQR)		7 (4-12)	7 (4-12)
HHC exposure to a hospitalised index – n (%)		62 (61)	244 (69)
HHC exposure to an index requiring ICU admission – n (%)		11 (19)	86 (35)
HHC exposure to an index who died – n (%)		8 (8)	33 (9)
Household IMD decile (IQR)		3 (2-6)	3 (2-6)
Time since index PCR diagnosis - median (IQR)		146 (125-181)	119 (93-157)
<b>Contact characteristics</b>			
contact female – n (%)		57 (56)	204 (58)

contact age – median (IQR)		44 (22-59)	42 (24-60)
days of exposure to index – median (IQR)		4 (1-10)	7 (3-14)
proximity to index <sup>2</sup> – n (%)	no close contact	19(19)	49(14)
	assisted in personal care	24 (24)	130 (37)
	shared bedroom	16 (16)	59 (17)
	shared bathroom	43 (42)	114 (32)
other COVID exposure (not index) – n (%)		26 (26)	107 (30)
COVID-19 diagnosis – n (%)		48 (47)	235 (67)
Contact symptoms - n (%)		40 (39)	183 (52)
Long COVID <sup>3</sup> - n (%)		4 (4)	8 (2)
vaccination status at time of serum sampling <sup>4</sup>	unvaccinated	49 (48)	169 (48)
	single vaccination	24 (24)	102 (29)
	double vaccination	29 (28)	81 (23)

424 <sup>1</sup> any of cough, dyspnoea, flu-like symptoms

425 <sup>2</sup> this variable captures the intensity of contact - level ‘0’ no close contact but still being a household member;

426 level ‘1’ sharing a bathroom but not sharing a bedroom; level ‘2’ sharing a bedroom but not providing physical

427 assistance; level ‘3’ ascribed to those providing physical assistance to the unwell index case including washing,  
428 dressing, feeding, assisting with movement

429 3 individuals with a clinical diagnosis of ‘Long COVID’

430 4 no more than 2 vaccinations available at this time

431

432 **Table 3. Unadjusted and adjusted odds ratios for the effect of index case Alpha SARS-CoV-2**  
433 **on household contact infection (defined as anti-nucleocapsid IgG seropositivity) compared to**  
434 **non-VOC**

	% NC positive (n/N)	Unadjusted OR (95% CI)	P- value	Adjusted OR*(95% CI)	P- value
<b>Non- VOC</b>	62% (63/102)				
<b>Alpha</b>	82% (289/352)	3.5 (1.7-7.4)	0.001	2.5 (1.2-5.4)	0.02

435 All OR are adjusted for household level clustering

436 \* adjusted for sex, age (years; linear), time between index PCR date and date of HHC serology (days; linear),  
437 duration of contact between infectious index and HHC (days; linear), IMD (rank; linear), intensity of contact (4  
438 levels assuming a linear trend).

439 NC = nucleocapsid, n = total positive, N = total population

440 **Table 4. Relationship between vaccination status, antibody positivity and the interval between**  
441 **household exposure (PCR positive test in index case) and serological testing of HHC**

Vaccination status	Serological response	Number of contacts  Total n=454	Interval between household exposure and serological testing	
			median	IQR
Unvaccinated Total 221	Spike positive  NC positive	166	117	91-147

	Spike positive NC negative	32	157	121-161
	Spike negative NC positive	3	198	143-198
	Spike negative NC negative	20	124	108-167
Vaccinated Total 233	Spike positive NC positive	183	133	108-161
	Spike positive NC negative	50	137	126-163
	Spike negative NC positive	0		
	Spike negative NC negative	0		

442

443

444

445

446

447

448

449 [Table 5. Unadjusted and adjusted odds ratios for the effect of index case Alpha variant SARS-](#)

450 [CoV-2 on household contact infection \(defined as either anti-nucleocapsid IgG seropositivity](#)

451 [or anti-spike IgG seropositivity in an unvaccinated individual\) compared to non-VOC SARS-](#)

452 [CoV-2](#)

453

	% infection (n/N)	Unadjusted OR (95% CI)	P- value	Adjusted OR*(95% CI)	P- value
<b>Non- VOC</b>	75% (77/102)				
<b>Alpha</b>	87% (307/352)	3.1 (1.2-8.3)	0.02	2.1 (0.8-5.5)	0.14

454 All OR are adjusted for household level clustering

455 \* adjusted for sex, age (years; linear), time between index PCR date and date of HHC serology (days; linear),

456 duration of contact between infectious index and HHC (days; linear), IMD (rank; linear), intensity of contact (4


457 levels assuming a linear trend)

458 n = total positive, N = total population

459

460 [Figure 1. Flow diagram for recruitment into the study](#)


461



462

463

464 Figure 2. Magnitude of anti-nucleocapsid SARS-CoV-2 antibody response in 454 household  
465 contacts with and without reported COVID symptoms



466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476

477 Appendix

478 Supplementary table 1. Baseline characteristics in 454 participant contacts with and 385

479 without serum samples

		Participants without serum samples	Participants with serum samples
Number of index - n			
	Alpha	162	188
	non-VOC	38	50
	total	200	238
Number of contacts - n		385	454
<b>Index characteristics'</b>			
index case female - n (%)		220 (57.1%)	255 (56.2%)
Index case age – median (IQR)		51 (40- 64)	57 (47-70)
ethnicity	white (%)	27 (54)	96 (51)
	Asian (%)	2 (4)	14 (8)
	Black (%)	7 (14)	34 (18)
	Middle Eastern (%)	5 (10)	15 (6)
	SE Asian (%)	7 (14)	13 (7)
	other	2 (4)	8 (4.3)

Hospital site	Hospital 1	49 (48)	173 (49)
	Hospital 2	53 (52)	179 (51)
household size <sup>a</sup> – median (IQR)		3 (2-4)	3 (2-4)
index case respiratory symptoms – n (%)		35 (70)	146 (78)
symptom duration in days – median (IQR)		7 (3-10)	7 (4-12)
index case hospitalisation – n (%)		29 (58)	124 (66)
index case ICU admission – n (%)		5 (17)	35 (29)
index case mortality – n(%)		1 (2)	2 (1)
IMD decile (IQR)		3 (2-6)	3 (2-5)
Time since index PCR diagnosis - median (IQR)		139(111-164)	130 (101-158)
<b>Contact characteristics<sup>b</sup></b>			
contact female – n (%)		172 (45)	204 (58)
contact age – median (IQR)		25 (12-45)	42 (24-60)
days of exposure to index – median (IQR)		5 (2-10)	7 (3-14)
proximity to index – n (%)	no close contact	86(22)	49(14)
	assisted in personal care	167 (43)	130 (37)

	shared bedroom	37 (10)	59 (17)
	shared bathroom	97 (25)	114 (32)
other covid exposure (not index) – n (%)		26 (26)	107 (30)
previous COVID-19 diagnosis – n (%)		48 (47)	235 (67)
Contact symptoms - n (%)		40 (39)	183 (52)
Long COVID - n (%)		4 (8)	8 (4)
vaccination status at time of serum sampling	unvaccinated	260(68)	169 (48)
	single vaccination	68(18)	102 (29)
	double vaccination	57(15)	81 (23)

480 <sup>1</sup> The index characteristic figures in the table refer to the number of household contacts for whom the  
481 corresponding index case had each given characteristic

482 <sup>2</sup>The contact characteristics figures in the table refer to the number of household contacts with each given  
483 characteristic

484

485

486


487

488


489

490

491 Supplementary Figure 1



Supplementary Figure 2




492  
493 Supplementary Figure 1. Density plot showing participant recruitment from time of index PCR  
494 diagnosis by SARS-CoV-2 variant of their index case.

495  
496 Supplementary Figure 2. Log normalised anti-NC SARS-CoV-2 antibody titre in household  
497 contact against time since index PCR SARS-CoV-2 diagnosis

498  
499 Supplementary Figure 3. Calculating the secondary outcome with infection defined as either  
500 anti-NC IgG seropositivity in any subject or anti-spike IgG seropositivity in an unvaccinated  
501 subject with S positive unvaccinated results

**Total antibody positive HHC indicating previous infection = 384/454 (85%)**



502

503

504